Incidences of new prescribing by British child and adolescent psychiatrists: A prospective study over 12 months

Journal of Psychopharmacology

Volumn 18, Issue 1, 2004, Pages 115-120

  Clark, Andrew F ^a,b  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b GREATER MANCHESTER MENTAL HEALTH NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Child mental health; Paediatric psychopharmacology; Prescribing practices; Psychiatric practice

Indexed keywords

ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ANTIHISTAMINIC AGENT; ANTIPARKINSON AGENT; ANXIOLYTIC AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CENTRAL STIMULANT AGENT; CLONIDINE; DEXAMPHETAMINE; FLUOXETINE; HYPNOTIC SEDATIVE AGENT; IMIPRAMINE; LAXATIVE; MELATONIN; METHYLPHENIDATE; PAROXETINE; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR; TRANQUILIZER;

ADJUSTMENT DISORDER; ANXIETY DISORDER; CHILD PSYCHIATRY; CLINICAL TRIAL; CONDUCT DISORDER; CORRELATION ANALYSIS; DEPRESSION; DEVELOPMENTAL DISORDER; DRUG USE; HUMAN; HYPERKINESIA; MENTAL HEALTH SERVICE; OBSESSIVE COMPULSIVE DISORDER; PHOBIA; PRESCRIPTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; PSYCHOPHARMACOTHERAPY; PSYCHOSIS; QUALITY CONTROL; REVIEW; SYSTEMATIC REVIEW; TIC; UNITED KINGDOM;

ADOLESCENT; AGE FACTORS; CHILD; CHILD PSYCHIATRY; CHILD, PRESCHOOL; ENGLAND; FEMALE; HUMANS; MALE; MENTAL DISORDERS; PHYSICIAN'S PRACTICE PATTERNS; PRESCRIPTIONS, DRUG; PROSPECTIVE STUDIES; PSYCHOTROPIC DRUGS;

EID: 2442529951     PISSN: 02698811     EISSN: None     Source Type: Journal    
DOI: 10.1177/0269881104040249     Document Type: Review

References (20)

1. Bramble D (2003) Annotation: the use of psychotropic medications in children: a British view. J Child Psychol Psychiatry 44: 169-179
2. British Association for Psychopharmacology (1997) Child and learning disability. Psychopharmacology. BAP concensus statement. J Psychopharmacol 11: 291-294
3. British Medical Association & Royal Pharmaceutical Society of Great Britain (2002) British National Formulary Number 44 (September 2002). British Medical Association & Royal Pharmaceutical Society of Great Britain, London
4. Conroy S, Choonara I, Impicciatore P, Mohn A, Amell H, Rane A, Knoeppel C, Seyberth H, Pandolfini C, Pia Raffaelli M, Rocchi F, Bonati M, 't Song G, de Hoog M, van den Anker S (2000) Survey of unlicensed and off label drug use in paediatric wards in European countries. BMJ 320: 79-82
5. Emslie G S, Rush J, Weinberg W A, Kowatch R A, Hughes C W, Carmody T, Rintelmann J (1997) A double-blind, randomized, placebo-controlled trial of fluoxetine in children and adolescents with depression. Arch Gen Psychiatry 54: 1031-1037
6. Gowers S G, Harrington R C, Whitton A, Lelliott P, Beevor A, Wing J, Jezzard R (1999) Brief scale for measuring the outcomes of emotional and behavioural disorders in children. Health of the Nation Outcome Scales for Children and Adolescents (HoNOSCA). Br J Psychiatry 174: 413-416
7. Greenhill L L, Halperin J M, Abikoff H (1999) Stimulant medications. J Am Acad Child Adolesc Psychiatry 38: 503-512
8. Hazell P, O'Connell D, Heathcote D, Robertson J, Henry D (1995) Efficacy of tricyclic antidepressants in treating child and adolescent depression: a meta-analysis. BMJ 310: 897-901
9. Jensen P S, Bhatara V S, Vitiello B, Hoagwood K, Feil M, Burke I. B (1999a) Psychoactive medication prescribing practices for US children: gaps between research and clinical practice. J Am Acad Child Adolesc Psychiatry 38: 557-565
10. Jensen P S, Kettle L, Roper M T, Sloan M T, Dulcan M K, Hoven C, Bird H R, Bauermeister J J, Payne J D (1999b) Are stimulants over-prescribed? Treatment of ADHD in four US communities. J Am Acad Child Adolesc Psychiatry 38: 797-804
11. Johnson J, Clark A F (2001) Prescribing of unlicensed medicines or licensed medicines for unlicensed applications in child and adolescent psychiatry. Psychiatr Bull 25: 465-466
12. Keller M B, Ryan N D, Strober M, Klein R G, Kutcher S P, Birmaher B, Hagino O R, Koplewicz H, Carlson G A, Clarke G N, Emslie G J, Feinberg D, Geller B, Kusumakar V, Papatheodorou G, Sack W H, Sweeney M, Wagner K D, Weller E B, Winters N C, Oakes R, McCafferty J P (2001) Efficacy of paroxetine in the treatment of adolescent major depression: a randomized, controlled trial. J Am Acad Child Adolesc Psychiatry 40: 762-772
13. Kumra S, Frazier J A, Jacobsen L K, McKenna K, Gordon C T, Lenane M C, Hamburger S D, Smith A K, Albus K E, Alaghband-Rad J, Rapoport J L (1996) Childhood onset schizophrenia: a double blind clozapine haloperidol comparison. Arch Gen Psychiatry 53: 1090-1097
14. March J S, Biederman J, Wolkow R, Safferman A, Mardekian J, Cook E H, Cutler N R, Dominguez R, Ferguson J, Muller B, Riesenberg R, Rosenthal M, Sallee F R, Wagner K D, Steiner H (1998) Sertraline in children and adolescents with obsessive-compulsive disorder: a multi-center randomized controlled trial. JAMA 280: 1752-1756
15. McNicholas F (2001) Prescribing practices of child psychiatrists in the UK. Child Psychol Psychiatry Rev 6: 166-171
16. Phillips T, Salmon G, James A C (2003) Prescribing practices in child and adolescent psychiatry: change over time 1993-2000. Child Adol Ment Health 8: 23-28
17. Riddle M A, Scahil L, King R A, Hardin M T, Anderson G M, Ort S I, Smith J C, Leckman J F, Cohen D J (1992) Double-blind, crossover trial of fluoxetine and placebo in children and adolescents with obsessive-compulsive disorder. J Am Acad Child Adolesc Psychiatry 31: 1062-1069
18. Royal College of Paediatrics and Child Health (2000) The use of unlicensed medicines or licensed medicines for unlicensed applications in paediatric practice. Royal College of Paediatrics and Child Health, London
19. Shaffer D, Gould M, Brasic J, Ambrosini P, Fischer P, Bird H, Aluwahlia S (1983) A Children's Global Assessment Scale (CGAS). Arch Gen Psychiatry 40: 1228-1231
20. World Health Organization (1992) The ICD-10 classification of mental and behavioural disorders: clinical descriptions and diagnostic guidelines. World Health Organization, Geneva